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Current and prospective pharmacotherapies for the treatment of pleural mesothelioma 
 
Abstract 
 
Introduction 
 
Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015-
2030. Therapies remain ineffective, thus developing and testing novel treatments is important 
for both oncologists and researchers. 
 
Areas Covered 
 
After describing mesothelioma and the shortcomings of current therapies, the article discusses 
numerous therapies in turn such as immunotherapy (passive and active), gene therapy (such as 
suicide gene therapy) and targeted therapy such as tyrosine kinase inhibitors. The bases for 
different therapies and clinical trials at different phases are also described. The article 
concludes by detailing possible reasons for therapy failure. 
 
Expert Opinion 
 
Despite the many attempts to uncover new therapeutic options, mesothelioma is still an orphan 
disease, complicated by factors such as the inflammatory microenvironment and low 
mutational load. Our opinion is that uncovering the biological mechanisms behind 
mesothelioma development will assist therapy development. The lack of efficacy of tyrosine 
kinase inhibitors and modest anti-angiogenic activity indicates a less relevant role for tumour 
cell proliferation and neoangiogenesis, thus the shortcut of treating mesothelioma with 
therapies from other cancers may be unsound. Conversely, many lines of evidence indicate that 
focussing on the survival mechanisms that tumour cells exploit may yield better therapeutics, 
particularly nutrition and cellular machinery. 
 
1. Introduction 
 
Mesothelioma is an uncommon form of cancer arising from mesothelial cells which line the 
membranes of organs including the heart (pericardial mesothelioma), testes (testicular 
mesothelioma), abdomen (peritoneal mesothelioma) and the lungs (pleural mesothelioma) 1. 
Of these four subtypes, peritoneal and pleural mesothelioma account for the vast majority of 
cases in mesothelioma (upwards of 90%), whilst pleural mesothelioma is overall the most 
prevalent, accounting for 68-85% of all mesothelioma cases 2. 
 
Malignant pleural mesothelioma (MPM) affects significantly more men than women, at a ratio 
of 4:1, usually at advanced age (>65 years old) 3. More men than women are affected by the 
disease due to workplace exposure. Approximately 2500 cases of MPM occur per year in the 
United States per year, whilst 5000 patients in Western Europe die from the disease each year 
3. Although a rare disease, there is an urgent need to develop new therapeutics as the fatalities 
from the disease are expected to increase over the next few years, in part due to the long latency 
period (approximately 50 years) from asbestos exposure to disease onset 4, 5. It is anticipated 
that the disease incidence will plateau between 2015-2030, and given the poor clinical outcome 
of current treatments there is a clear, urgent need to develop new therapeutics to improve 
patient care and address the oncoming surge of MPM cases 5. 
 
This review will cover current treatment options for malignant pleural mesothelioma – both 
pharmacotherapies and other options such as surgery – in addition to discussing prospective 
novel therapies for the disease. A variety of topics will be discussed, including drugs used in 
the clinic at present such as cisplatin, pemetrexed and gemcitabine, as well as 
immunotherapeutic options such as tremelimumab and other immune checkpoint inhibitors 
such as nivolumab and pembrolizumab that are currently under investigation in early phase 
clinical trials. Lastly, the review closes with an Expert Opinion summarising the contents of 
the article and arguing the strengths and weaknesses of the different approaches discussed 
throughout the review. 
 
2. Body 
 
2.1 Current treatments for mesothelioma 
 
As stated in the Introduction, malignant pleural mesothelioma presents an unmet challenge due 
to the anticipated surge in cases in the coming years and the current poor clinical outcome. 
There is also a high interest in this cancer due to it being largely a man-made epidemic through 
the use of asbestos 6. Despite it being established that asbestos is linked to MPM development, 
many countries have been slow to implement its removal, thus elevating the chances of further 
diagnoses in the future. Further complicating the issue is the fact that the fire-retardant and 
insulating properties of asbestos mean that it has been used as part of the structural support of 
numerous buildings, and should these buildings be damaged millions of people could be 
exposed to it and potentially develop mesothelioma 3. 
 
MPM is treated in different ways (including surgery, radiotherapy and chemotherapy) which 
may vary depending on the stage of the cancer. Stage I MPM is characterised by minimal 
tumour growth, isolated to the parietal pleura with possible involvement of the visceral pleura. 
Stage II MPM is characterised by superficial tumour growth on all pleural membranes, or 
involvement of the diaphragmatic muscle or lung parenchyma. Notably, Stage I and II MPM 
patients have a tumour that may be resectable and thus treatable by surgery 3. However, patients 
are commonly diagnosed at later stages, reducing the treatability of the disease by surgery. 
 
Stage III MPM represents the most common stage at clinical diagnosis, and represents patients 
whose tumour has metastasised to areas such as lymph nodes, whilst Stage IV is characterised 
by the tumour invading the spine or ribs, with potential distant metastases, as well as other key 
clinical features 3. 
 
Unfortunately, no treatment regimen for MPM has demonstrated real capability to improve 
these patients’ survival even though standard therapies for MPM do exist. They are of two 
kinds: one with more “curative” intent, and the other as palliative care to provide relief from 
symptoms. Opinions on suggested criteria for which approach is taken have been detailed 
previously 5 such as deciding that curative intent should be taken if the patient is below seventy 
years old, has a cancer not in the advanced stages, has no significant cardiopulmonary 
complications, and has no relevant accompanying disease, whilst palliative care may be 
employed when the patient has a poor general condition and nutritional state, has advanced 
stage cancer or has sarcomatoid or biphasic mesothelioma at any stage 5. Sarcomatoid 
mesothelioma, although a very rare form of mesothelioma, is a notoriously difficult cancer to 
treat and has a very poor clinical outcome 7. 
 
Early stages of the cancer may be treated by surgery, with the desirable outcome being 
complete resection of the tumour but this is applicable only for a minority of patients due to 
the fact that most diagnoses occur at advanced tumour stages 3, 8, 9. Surgery may also be used 
as a palliative therapy, serving to reduce symptoms and eliminate the bulk of the tumour mass 
(this is known as cytoreduction). Multiple types of surgery are employed, such as extrapleural 
pneumonectomy and pleurectomy/decortication 10. Surgery alone, for those with resectable 
tumours, improves clinical outcomes. However, more effective outcomes are obtained when 
surgery is combined with adjuvant therapy such as chemotherapy or radiotherapy, with survival 
increasing slightly from ten months to twenty months 8, 11, 12. Despite this, a systematic review 
carried out by Papaspyros and Papaspyros indicates that results from surgery are conflicting, 
with some studies indicating poor survival or no difference between patients treated surgically 
and those not, whilst the overall thought is that surgery as part of trimodality therapy offers 
long-term survival 13. However, the authors also indicated that specialised centres demonstrated 
better results, which may present a complication in translating observed therapeutic benefits to 
the wider population 13. 
 
In addition to surgery, adjuvant chemotherapy and radiotherapy may be used in the treatment 
of MPM. Preclinical studies have demonstrated that radiotherapy may enhance the efficacy of 
an immune checkpoint inhibitor, however data remains largely preliminary 8, 14. Ultimately, 
single-modality therapy is generally less effective than multimodal therapy. Adjuvant 
chemotherapy is also supposed to target distant metastases 9. 
 
The cornerstone of chemotherapy for MPM is platinum-based drugs such as cis-platinum, 
which are often in combination with anti-folate agents as first-line therapy for advanced stage 
MPM when the tumour cannot be resected 15. However, although some patients respond to this 
therapy there is no standard second-line therapy 16. Other chemotherapy drugs utilised in the 
treatment of MPM include etoposide, doxorubicin, pemetrexed and gemcitabine. Generally, 
combination treatments of different chemotherapeutic drugs have shown more effective 
outcomes 17. One combination that has been shown to achieve a slight improvement of survival 
is combination of pemetrexed with cisplatin 18, 19. However, although this study was an 
improvement in survival (of 2.8 months), successful therapy for MPM is obviously still 
lacking. 
 
The lack of effective therapy for MPM highlights a very clear need to develop novel 
compounds and treatments to address the poor survival rate. There are several emerging 
therapies for mesothelioma which are at different stages of clinical development and usage, 
one of which is immunotherapy. 
 
2.2 Immunotherapy 
 
Immunotherapy in general refers to the idea of killing the cancer cells not by drugs targeting 
the cancer cells, but by using drugs or other therapeutic agents to facilitate immune-mediated 
anti-tumour effects. For MPM, it has been shown that lymphocyte infiltration to the tumour 
correlated with better prognosis in patients, highlighting the justification and potential of 
harnessing the power of the immune system 20, 21. A detailed review on different approaches to 
immunotherapy for MPM can be found by Grégoire (2010) 21. 
 
Before developing immunotherapeutic treatments for mesothelioma, it is important to first 
understand the immunophenotype of mesothelioma patients. Studies have shown that although 
leukocyte counts in patients were not altered overall, there was a shift in the subtypes that 
promoted tumour growth – for example there was a marked reduction in the levels of cytotoxic 
t-lymphocytes 21, 22. It has been shown in several cases that lymphocytes infiltrate the solid 
mesothelioma tumour and that immune cell-tumour associations are also present in pleural 
effusions; however, despite this, immune systems of patients are often tolerant towards the 
cancer growth 21, 23. Thus enhanced understanding of the reasons behind this is crucially 
important prior to designing immunotherapeutic agents, so as to target the facets of the immune 
system that are over- or underactive. 
 
The immune response can be harnessed for therapeutic targets through passive immunotherapy 
and active immunotherapy. Passive immunotherapy has been described as an approach 
whereby effectors are isolated, “trained” in vitro and then re-injected into the patient to promote 
an anti-tumour effect. By contrast, active or adaptive immunotherapy refers to the approach of 
stimulating the immune system (i.e. through antigen presentation), thus triggering an immune 
response against the cancer. 21. Generally, one problem with passive immunotherapy is that it 
is probable that the therapeutic benefit will be short-term, whereas active immunotherapy may 
have a more long-term approach to disease control 24. 
 
2.2.1 Passive Immunotherapy 
 
There are numerous approaches to passive immunotherapy such as the use of cytokines, 
monoclonal antibodies, and activated T-lymphocytes 18, 21. It has been shown that cytokines 
such as interleukins stimulate the immune system against viruses and tumours, and it is 
hypothesised that this stimulation could be harvested to reduce tumour growth. One phase II 
study utilised interleukin-2 treatment for mesothelioma patients and found that those who 
responded to therapy had a statistically significant increase in median survival compared to 
non-responders 25. However, conflicting findings on interleukin-2 treatment have been reported 
18, potentially due to different administration methods, and toxicity and side-effects of 
interleukin-2 treatment have been reported 26 This and the conflicting reports provide a clear 
example of the challenge of harnessing the power of the immune system. 
 
Although immune checkpoints are crucial within a healthy body for regulating self-tolerance 
and protecting healthy tissues during the immune response, it is increasingly clear that immune 
checkpoints are hijacked during the process of cancer development – for comprehensive 
coverage of blocking immune checkpoints in cancer as therapy, see Pardoll (2012) 27. In brief, 
tumour resistance to the immune system typically arises through overexpression of inhibitory 
ligands that blunt T-cell effector functions, with this overexpression occurring either on the 
tumour cells or on other cells within the tumour microenvironment. In contrast, however, 
tumour-mediated immune evasion is not generally due to overexpression of factors that 
stimulate T-cell activation 27. 
 
Therefore one approach that is currently receiving a significant amount of attention is the use 
of immune checkpoint inhibitors. .Although there was promising data (and FDA approval) for 
other cancer types 28, this success has not yet transferred to mesothelioma. There is much focus 
on blockage of PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte 
associated protein 4) which are two key negative regulators of the immune system 28. CTLA-4 
is under particular scrutiny due to the fact that ipilimumab, another antibody against it, has 
been approved for the treatment of melanoma 29. Immune checkpoint blockade in 
mesothelioma has been comprehensively reviewed by Marcq and colleagues 30 
 
Tremelimumab is a monoclonal antibody against CTLA-4 (similar to ipilimumab), which is 
currently under investigation in clinical trials. Unfortunately, an announcement by AstraZeneca 
stated that tremelimumab as a monotherapy does not significantly improve survival and that 
the end point of the study was not reached 31. At the American Society of Clinical Oncology 
2016 meeting, data on the DETERMINE trial (ClinicalTrials.gov identifier NCT01843374) 
was presented, consisting of 571 patients either untreated or treated with tremelimumab as a 
second or third-line therapy 32. Unfortunately again, 81% of the patients died and there was no 
statistically significant difference between placebo and treated patients in terms of survival. 
Ultimately despite the sound scientific justification the use of monoclonal antibodies to 
immune check point inhibitors is still in its early stages for MPM and thus requires significantly 
more research (especially randomized clinical trials exploring the impact of these drugs on 
patients’ overall survival)  so as to not to misinform those who suffer from this disease, both 
directly and indirectly. 
 
PD-1, the other primary immune checkpoint marker of interest, has also been under 
investigation. Pembrolizumab is a monoclonal antibody that blocks the interaction of PD-1 
with its ligand, which should lead to a removal of the inhibition of T-cell activity against the 
cancer. The findings of a clinical trial (KEYNOTE-028) demonstrated that the drug was well-
tolerated by patients and demonstrated a robust anti-tumour effect in patients with PD-1 ligand-
positive MPM 33. Though promising, and although this highlights potential therapeutic use of 
immunotherapy, antibodies against other targets have shown less positive results. 
 
The potential of combination immunotherapy against multiple markers has also been assessed. 
Another PD-1 inhibitor is nivolumab, which again has been approved for treatment of 
melanoma 34, though its use in mesothelioma is less well-established. One phase II clinical trial 
(NCT02716272) is investigating the combination of nivolumab (to inhibit PD-1) with 
ipilimumab (to inhibit CTLA-4) in mesothelioma, though results are yet to be released. 
Combination of nivolumab with ipilimumab has already been carried out for other cancer types, 
providing the basis for this approach 35. Other clinical trials investigating nivolumab in 
mesothelioma are NCT02341625, NCT02497508 and NCT02899299, though these are all in 
the recruitment stage or are ongoing. Combination immunotherapy for melanoma, using 
nivolumab and ipilimumab, demonstrated high rates of side-effects (with them occurring in 
55% of patients) at grade three or four 36. This thus also represents an additional factor when 
investigating the potential of combination immunotherapy in mesothelioma. 
 
Although monoclonal antibody therapy is currently a “hot-topic” as an approach to 
immunotherapy, there are many other possibilities such as active immunotherapy. Active 
immunotherapy is the therapeutic approach whereby the aim is the education and activation of 
the immune system to attack cancer cells. There are different strategies that have been 
introduced in the clinical setting for MPM and they have raised the attention of medical 
professionals, being now in the centre of many discussions. 
 
2.2.2 Active Immunotherapy 
Active immunotherapy may involve therapeutic vaccines, with peptide and cell vaccines being 
approaches investigated under clinical examination. It has been demonstrated in an early 
clinical trial that Wilms tumor 1 (WT1), highly expressed in mesothelioma, when used as 
peptide vaccination induced quantifiable specific immune responses, although no clinical 
improvement was seen 37. Two clinical trials are currently ongoing using a derived product of 
WT1 alone or in combination with chemotherapy (NCT01890980 and NCT01265433). Other 
approaches include the use of modified bacterial organisms such as L. monocytogenes 
expressing mesothelin, which is overexpressed in mesothelioma and which may be involved in 
tumour invasion 38. This cancer vaccine (CRS-207) has been developed to promote an immune 
response against the tumour-associated antigen mesothelin and is currently part of an ongoing 
trial  (NCT01675765). 
 
Cell vaccines use dendritic cells loaded with tumour-associated antigens; the technique consists 
of ex vivo manipulation of these cells obtained by peripheral blood precursors and modification 
with a tumour-specific antigen, and then vaccinating the patient with these cells 39. There are 
several clinical trials and a few are completed (NCT00280982 and NCT01241682), whilst 
others are recruiting or their status is unknown (NCT02395679, NCT02649829 
NCT01291420). The phase 1 trial NCT00280982 showed that the vaccine was feasible, well-
tolerated, and cytotoxic activity against autologous tumour cells was detected in a subgroup of 
patients 40. 
 
 
2.3 Gene Therapy 
 
One other mode of therapy which is attracting many researchers is gene therapy, which is a 
new strategy consisting of genetic manipulation for a therapeutic purpose. It has been shown 
that several genes are modified in mesothelioma and numerous preclinical studies using 
different genes and vector systems demonstrated a therapeutic effect with promising results for 
the clinical setting. Numerous vector systems are available for gene therapy, including (but not 
limited to) adenoviruses, vaccinia viruses and non-viral options such as antisense 
oligonucleotide therapy 41, 42. 
 
Adenoviruses represent the most common vector within gene therapy, and have previously 
been applied in both preclinical and clinical studies in mesothelioma. One study on 
immunocompetent Fischer rats demonstrated that the herpes simplex virus-thymidine kinase 
gene when carried by an adenovirus vector resulted in a reduction in tumour burden, though 
the authors also stated that only small increments in survival were seen 43. However, a similar 
approach was later utilised at a Phase I trial, detailed below 44. The use of vaccinia vectors has 
also been shown, with vaccinia-vector-cytokine constructs that were intratumourally 
administered demonstrating tumour regression 45. Non-viral approaches to gene therapy have 
been demonstrated to be effective in mesothelioma cell lines, with Smythe and colleagues 
demonstrating that antisense oligonucleotides against Bcl-xL, an anti-apoptotic member of the 
Bcl-2 family, promoted apoptosis with or without liposomal delivery 42. 
 
One form of gene therapy is suicide gene therapy, which uses a virus to deliver a transgene 
which encodes for a specific enzyme that metabolises prodrugs into toxic metabolites, leading 
to tumour cell death or “suicide” 46.  A Phase I trial investigated the potential of suicide gene 
therapy in mesothelioma 44.  The intrapleural administration of this treatment was safe and well 
tolerated in mesothelioma patients. 34 patients were enrolled but only 2 resulted in long-term 
durable responses, though as a Phase I study it is too preliminary to draw any conclusions.  
 
As previously mentioned, cytokines represent a potential route through which therapy can be 
improved. Cytokine gene therapy is a genetic manipulation strategy which uses a viral vector 
encoding a specific cytokine (such as interleukin-2 [IL-2], IL-12, tumour necrosis factor [TNF] 
or interferons [INF -α, β, or γ]) to increase their expression, triggering a direct cytotoxic effect 
on tumour cells 47. This approach has the advantage of reducing toxicity and increases the local 
concentration of these molecules. A phase I study was conducted to evaluate the safety and 
feasibility of single-dose intrapleural IFN-β gene transfer using an adenoviral vector (Ad.IFN-
β) in mesothelioma patients, which showed that it was generally well-tolerated and that 
transient lymphopenia was the most common side-effect 48. Antitumour immune responses 
were seen in 70% of the patients, whilst 40% of patients showed a meaningful clinical response 
(as assessed by disease stability and/or regression). Two clinical trials (Phase I) as gene therapy 
alone for MPM patients have been under assessment and their status is either ongoing or 
unknown (NCT00299962, NCT00066404).  
 
Another gene therapy strategy is using genetically modified T cells engineered with lentiviral 
or retroviral vectors to produce T-cell receptors that will specifically attack cancer cells 49. An 
in vivo study showed that antimesothelin-engineered T-cells recognised mesothelin-expressing 
cells and induced significant tumour regression 50. A current phase I study “Autologous 
Redirected RNA Meso-CIR T Cells” is ongoing (NCT01355965). Another target that can be 
attractive for gene therapy is fibroblast activation protein (FAP) since it appears to be mainly 
expressed on the surface of reactive tumour-associated fibroblasts as well cancer cells. 
Schuberth and colleagues demonstrated that re-directed T cells specific for FAP were cytotoxic 
towards FAP positive targets in vitro and in vivo 51, supporting a phase I trial that is currently 
recruiting to evaluate the safety of a single administration of adoptively transferred FAP-
specific re-directed T cells (NCT01722149). 
 
2.4 Targeted Therapy 
 
Although the molecular mechanisms involved in MPM are still unclear, in recent years 
promising pathways have attracted the attention of translational medicine researchers, and as a 
result several drugs are in the development pipeline and at various stages of preclinical and 
clinical studies. The main molecules under investigation are responsible for molecular 
signalling and the aforementioned immune response. Examples of approaches include targeted 
therapy (direct action against cancer-specific molecules and signalling pathways, resulting in 
limited nonspecific toxicity), tyrosine-kinase inhibitors, epidermal growth factor receptor 
(EGFR) targeting, vascular endothelial growth factor (VEGF) targeting and RNA targeting. 
 
Recently small molecule inhibitors, which are able to pass through the membrane and interact 
with the intracellular domain of receptors and downstream intracellular signalling, have been 
studied, such as tyrosine kinase inhibitors (TKIs) 52.   
 
2.4.1 Tyrosine Kinase Inhibitors Against EGFR 
 
TKIs are primarily effective in the targeted treatment of various malignancies and most of them 
act as competitor with the ATP binding site of the catalytic domain of numerous tyrosine 
kinases 53. TKIs are oral drugs with an established safety profile and can be efficiently 
combined with other forms of treatment including chemotherapy or radiation therapy 54. 
Numerous TKIs have showed an effective antitumor activity in various cancer types and have 
been approved for the clinic. TKIs are currently under investigation in mesothelioma.  
 
EGFR is one such target of TKIs, which is involved in downstream signalling pathways related 
to oncogenes and activates the RAS/RAF/MAPK cascade which plays a role in cell 
proliferation, metastasis, and invasion 55 and the PI3KCA/AKT/mTOR pathway, which 
determines the inhibition of apoptosis 56. Therefore, abnormal EGFR signalling contributes to 
the development of a malignant phenotype in several varieties of epithelial cancers as well as 
MPM 57, 58. It has been reported that EGFR is overexpressed in 60–70% of MPM tissue 
specimens 59 and inhibition of EGFR-dependent signalling pathways in mesothelioma cell lines 
also causes reduced cell survival 57. Gefinitib (ZD1839, Iressa), a potent TKI has been studied 
in a phase II study in 43 patients with unresectable disease but it was not active despite the fact 
that in 97% of patients EGFR was overexpressed 60. Another EGFR TKI, erlotinib (OSI-774, 
Tarceva) was used in a phase II trial in previously untreated patients with MPM but single-
agent erlotinib was not effective 61. Another clinical trial of erlotinib (Tarceva) plus 
bevacizumab (Avastin) in previously treated patients with MPM did not show an effective 
response 62. One of the major obstacles for the use of TKIs against EGFR in mesothelioma is 
that although EGFR is overexpressed in the majority of MPM patients, this overexpression 
does not correlate with clinical outcomes following use of TKIs 63. Elucidation for clinical 
failure may be that mutations analysed in patients with other malignancies may not be different 
from MPM patients 59, or alternatively the frequency of mutation may be too low in 
mesothelioma patients 64, resulting in the lack of clinical response in non-selected patients. 
 
Another class of EGFR inhibitors is anti-EGFR monoclonal antibodies (mABs), which interact 
with the extracellular domain of EGFR, competing with EGF ligand. Cetumixab (Ertibux) 
showed a therapeutic efficacy on blocking cell growth in MPM cell lines and mouse models 65 
and a phase II study with cetuximab in combination with cisplatin or carboplatin/pemetrexed 
as first line treatment has been completed, though no study results have yet been posted 
(NCT00996567). 
 
2.4.2 Tyrosine Kinase Inhibitors Against VEGF 
 
Neoangiogenesis is a hallmark of cancer which contributes to tumour growth and metastatic 
dissemination 66. It is well-established that vascular VEGF is the most powerful angiogenic 
promoter, released by several malignancies including MPM 67, 68. The role of VEGF has been 
detected in MPM in studies, showing high levels (detected by immunohistochemistry) in the 
tissue specimens of patients with MPM 69 and as free circulating molecules 70. All this evidence 
has highlighted that an anti-VEFG therapy could have a therapeutic effect in MPM patients. 
 
VEGF or VEGF receptor (VEGFR) inhibitors have been used in several clinical trials as a 
single therapy or in combination with chemotherapy for MPM patients as reported in Table 1. 
Bevacizumab (Avastin), a humanized monoclonal antibody against VEGF, the most potent 
growth factor involved in tumour angiogenesis, was approved in the EU in 2005 for the 
treatment of carcinoma, non-small-cell lung cancer, colorectal cancer, carcinoma, renal cell 
cancer, and ovarian cancers 71-74 . Bevacizumab has been evaluated as first-line treatment in a 
phase II clinical trial with cisplatin and pemetrexed in patients with advanced mesothelioma. 
The trial failed to achieve the primary endpoint 75. A phase III multicentre, randomized, 
controlled study of bevacizumab in addition to cisplatin and pemetrexed in untreated 
mesothelioma patients has also been carried out 76. The overall survival was statistically 
significantly longer in patients treated with the triple therapy regimen than cisplatin and 
pemetrexed. Though statistically significant the difference was only 2.7 months, highlighting 
the need for further research. The majority of VEGFR tyrosine kinase inhibitors such as 
vatalanib (PTK787/ZK 222584), sorafenib, sunitinib, imatinib, and cediranib (AZD2171) have 
been studied in MPM and have shown limited or absent levels of activity, resulting in a lack of 
clinical benefits 77-82. Nintedanib (BIBF 1120), an oral potent triple angiokinase inhibitor, is 
under investigation in two Phase II clinical trials as single treatment and in combination with 
pemetrexed and cisplatin followed by maintenance nintedanib compared with chemotherapy 
alone in patients with unresectable MPM (NCT02568449, NCT01907100, respectively).  
 
2.4.2 Histone Deacetylase (HDAC) Inhibition 
 
Another class of drugs that are under investigation as targeted therapy include vorinostat and 
belinostat, drugs with inhibitory activity against histone deacetylase (HDAC) enzymes, which 
control gene expression through histone modifications 83 and it has been demonstrated that 
HDAC  inhibitors promote susceptibility of mesothelioma cell lines to tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) 84. Vorinostat, one of the common HDAC 
inhibitors, has shown activity against mesothelioma in phase I trials 85. A phase III, multicentre 
trial (VINTAGE-014) of vorinostat versus placebo as a second-line or third-line therapy failed 
to show an improved overall survival 86. A phase II trial with Belinostat (PXD 101) as second-
line therapy in advanced mesothelioma did not show clinical activity 87. 
 
2.4.3 Focal Adhesion Kinase (FAK) Inhibition 
 
One the most frequently mutated tumour suppressor genes detected in mesothelioma cells is 
NF2, which inactivates merlin (the protein product of the NF2 gene) and results in an increase 
of the activity of focal adhesion kinase (FAK). FAK is a cytoplasmic protein, a tyrosine kinase 
that is involved in cell proliferation, survival, migration, invasion and cancer stem cell (CSC) 
renewal 88. A study reported that FAK was overexpressed in mesothelioma cell lines and 
implicated in promoting invasiveness 89. Defactinib (VS-6063) is a highly potent, selective 
FAK inhibitor. A phase II randomized multicenter trial (COMMAND) of defactinib in 
previously treated MPM was performed but the study has been terminated to lack of efficacy 
(NCT01870609). Recently another FAK inhibitor (GSK2256098), has been tested in a phase I 
study in patients with advanced cancer, including mesothelioma patients 90.  The initial 
pharmacologic and pharmacokinetic studies showed an acceptable and safe profile in patients 
with mesothelioma, in particular those harbouring merlin loss 90. In addition, another phase I 
trial has been completed, though no study results have been posted yet (NCT01938443). This 
study investigated the effect of dose escalation of GSK2256098 in combination with 
trametinib, a mitogen-activated protein kinase (MEK) inhibitor in patients with advanced solid 
tumours, including mesothelioma. 
 
2.4.4 Other Targeted Therapies 
 
Bortezomib is a selective inhibitor that acts via downregulation of nuclear factor-κB and thus 
promotes apoptosis. A phase II study investigating the activity of Bortezomib as first-line and 
second-line therapy in MPM patients demonstrated a lack of clinical activity and thus did not 
warrant further investigations 91. 
 
In addition to the above is BNC105P, an inhibitor that selectively blocks tubulin, which through 
polymerisation promotes cancer cell proliferation. It showed effective activity in preclinical 
and phase I studies 92. A phase II study with BNC105P investigated its efficacy and safety as 
second line therapy in MPM but the response was insufficient to justify further studies 92. 
 
Cixutumumab (Agent IMC-A12) is a humanized antibody against insulin growth factor-I 
receptor (IGF-IR), which in cooperation with its ligands (IGF-I) play a role in cell proliferation, 
invasion, and metastasis though IGF signalling pathway 93. A study demonstrated that 
cixutumumab decreased the growth of mesothelioma compared to the control group in in vivo 
models 93. A phase II clinical trial of cixutumumab in previously treated patients with MPM is 
currently ongoing (NCT01160458). 
 
Another example of targeted therapy which involves RNA as a therapeutic target is ranpirnase 
which targets tRNA and is able to promote impaired protein synthesis and cell cycle arrest, 
showed that it has an antitumor activity 94. In mesothelioma cell lines, ranpirnase inhibited cell 
growth, both in vitro and in vivo 95. A phase II study with ranpirnase as single drug in untreated 
patients has showed that ranpirnase may have an activity and a tolerable toxicity profile and 
phase III trial of ranpirnase was conducted in comparison with single-agent doxorubicin 
showing no significant difference (only 2 months; 11.3 vs 9.1 months) 94. Another phase III 
randomized study was conducted with ONCONASE (ranpirnase) plus doxorubicin versus 
doxorubicin alone 94. The clinical outcomes, however, are not yet available. 
 
Human tumour necrosis factor-alpha (hTNF-α), has an antitumor activity in many solid 
tumours, including malignant mesothelioma 96. However, several studies have shown that 
administration of hTNF-α lead to a toxic effect, and therefore NGR-hTNF-α has been 
developed as a fusion protein with a cyclic tumour-homing peptide (CNGRCG), asparagine-
glycine-arginine and tested in a phase II as maintenance treatment in patients with advanced 
MPM. At the moment this study is recruiting participants (NCT01358084). NGR015 is a 
randomized double-blind phase III study of NGR-hTNF-α plus Best Investigator’s Choice 
(BIC, a choice of different chemotherapy drugs) versus placebo plus BIC as second line therapy 
in patients with advanced MPM is also ongoing but not recruiting participants (NCT01098266). 
 
GC1008 is an anti–TGFβ antibody. TGFβ is involved in tumour progression due to its abilities 
to stimulate vessel formation, modify the stromal environment, and, mainly, promote local and 
systemic immunosuppression 97. Additional investigational strategies evaluated the role of heat 
shock protein 90 (HSP90) inhibitor (ganetespib), enhancer of zeste homolog 2 (EZH2) inhibitor 
(Tazemetostat), inhibitor of the MET receptor tyrosine kinase (Tivantinib), Cancer Stem Cell 
(CSC) inhibitor (Napabucasin/BBI608) and TargomiRs (a mimic microRNA treatment). These 
trials are all active trials and some of them are recruiting (Table 1). 
 
 
2.5 Conclusions 
 
The lack of effective treatment for mesothelioma highlights an urgent need to develop novel 
therapeutics. It is surprising that treatments which are proven effective for other cancer types 
such as tyrosine kinase inhibitors do not show clinical benefit for mesothelioma. Although 
immunotherapy has been successfully applied to melanoma, immune checkpoint blockade 
requires more research before its application to treat mesothelioma due to recent clinical trials 
setbacks. Similarly, the failure of many clinical trials for other promising therapies remains 
problematic. Isolating the driving issues behind the failure of these treatments to show 
significant effects may assist in resolving this long-standing issue. 
 
Possible causes for failure of these therapies at the clinical level are numerous. Immunotherapy, 
despite high hopes for approaches such as immune checkpoint blockade, has generally not 
resulted in a clinical benefit for mesothelioma. Primarily, it has been shown useful for 
melanoma and side-effects have been observed 28. Resistance to immune checkpoint inhibition 
has been indicated to arise through stromal cells mediated by chemokine (C-X-C motif) ligand 
12 (CXCL12) which promoted immune evasion, based on   model of pancreatic ductal 
adenocarcinoma 98. FAP has been shown to be expressed on tumour-associated fibroblasts and 
cancer cells, and use of human CD8+ T cells transduced with anti-FAP demonstrated growth 
inhibition of FAP-positive tumour cells 51, thus providing further evidence for the role of the 
stroma.  It has been argued that once the toxicity of the immune checkpoint inhibitors reaches 
acceptable levels approaches such as combination checkpoint therapy could be employed, or 
their role as adjuvant therapy considered 29. However, further research is required prior to the 
clinic for immune checkpoint blockade in mesothelioma. 
 
Mesothelioma is a cancer characterised by a low mutational load, which may represent an 
explanation for the failure of TKIs. For instance, it has been demonstrated that in peritoneal 
mesothelioma, patients lack the EGFR mutations that would render them sensitive to TKIs 99. 
Similarly, in a patient cohort (n=38) of pleural and peritoneal mesothelioma, EGFR mutations 
were detected only in six (16%) patients 100. An additional factor that may contribute towards 
therapy failure is the hypoxic environment that defines mesothelioma. It has been shown that 
hypoxia induces NOTCH1 whose inhibition promoted apoptosis in mesothelioma cells 101. 
Furthermore, hypoxia has also been shown to promote motility and invasiveness of MPM cells 
102. Thus, characterisation of the effects of hypoxia on the tumour cell’s gene expression profile 
could represent a route through which therapies could be improved. 
 
Ultimately further research is required to improve therapeutic outcomes. A significant effort 
has been employed to discover new therapies for mesothelioma yet this cancer remains difficult 
to treat. It is possible that a focus on different pathways may yield improved outcomes, as 
expanded upon in the Expert Opinion. 
 
3. Expert Opinion 
 
Despite the attempts to find new therapeutic routes, MPM is still an “orphan” disease and the 
lack of treatment really improving the prognosis of these tumours is urging us to take action. 
 
There is no doubt that any achievement for this tumour should be based on a better 
understanding of the genetic and biological mechanisms underlying its carcinogenesis and 
progression. The inflammatory microenvironment (including the stromal cells), the low 
mutational load, along with the marked immune suppression are just some of the features that 
pose as difficult hurdles to the identification of new treatments. 
 
The asbestos fibre-dependent inflammation affects the immune response, whereas the low 
mutational load of MPM cells does not allow the expression on a sufficient “battery” of neo- 
antigens necessary to trigger a robust immune reaction. On the other hand, the role of tumour 
cell proliferation and neoangiogenesis looks to be significantly less relevant than in other 
tumours if one considers the lack of efficacy or the modest activity of the treatment of this 
tumour with TKIs or anti-angiogenic agents respectively. The absence of driving genes and the 
onset of selective pressure exerted by TKIs provide a possible explanation of the failure of 
these therapies for MPM and prompt us to rethink their use i.e. combined treatments and 
alternative pathways of growth. 
 
Therefore it seems clear that the shortcut of treating MPM with drugs because they have shown 
a certain degree of activity in other tumour is likely not to be the best option.  
 
As opposite it is imperative to explore new avenues offered by the mechanism that MPM cells 
exploit to survive within the hostile microenvironment and with particular attention to the type 
of nutrients and their cell machinery. With regard to this  other authors have already shown 
how MPM  is an extremely hypoxic tumour 101, 103, 104 and we have already demonstrated how 
MPM cell metabolisms is highly dependent on glycolysis, providing the evidence for targeting 
this metabolic reprogramming 105. 
 Eventually, if one considers the current front line therapy for MPM is the combination 
treatment of chemotherapy plus antiangiogenic agents 76 improves the survival only by three 
months compared to chemotherapy alone, it is clear that more research is the first mandatory 
step in the direction of more effective treatments for MPM. 
 
  
Highlights Box 
1) Current treatments for mesothelioma do not significantly enhance survival 
2) Despite the application of immunotherapy in melanoma treatment, challenges 
remain for this therapy to be effective for mesothelioma 
3) The use of targeted therapy may lead to improved clinical outcomes, however 
the presence of protein overexpression and use of inhibitors does not always 
follow through at the clinical level 
4) Although neoangiogenesis and VEGF expression are undoubtedly a feature of 
mesothelioma, anti-VEGF/R treatments do not appear to have a clinical benefit, 
excepting triple combination therapy with cisplatin and pemetrexed which 
extends survival by 2.7 months 
5) Improved understanding of the basic mechanisms mesothelioma cells use to 
survive in their hostile environment (with particular attention on nutrition and 
cellular machinery) could lead to new development pipelines and therapeutic 
possibilities 
 Table 1: Summary of completed and ongoing clinical trials in mesothelioma  
 
Intervention Clinical trial N patients  Phase Status 
Immunotherapy 
strategies 
    
 
Immune checkpoint 
blockade 
 
    
 
Pembrolizumab 
 
NCT02054806 
 
477 
 
I 
 
 
ongoing 
 
 
Nivolumab 
 
NCT02716272 
NCT02341625 
NCT02497508 
NCT02899299 
 
 
125 
407* 
33 
600* 
 
II 
I/II 
II 
III 
 
ongoing 
recruiting 
ongoing 
recruiting 
 
 
Tremelimumab 
 
 
NCT01843374 
 
658 
 
II 
 
ongoing 
 
Wilms Tumor-1 (WT1) 
vaccine 
    
 
WT-1-vaccine 
Montanide 
 
 
NCT01890980 
NCT01265433 
 
60* 
31 
 
II 
II 
 
ongoing  
ongoing 
 
Anti mesothelin 
vaccine 
 
    
 
 CRS-207 
 
NCT01675765 
 
 
60 
 
I 
 
ongoing 
 
Dendritic Cell-based 
vaccine 
 
    
 
Tumour lysate-loaded 
autologous dendritic 
cells 
 
 
NCT00280982 
NCT01241682 
NCT02395679 
NCT02649829 
NCT01291420 
 
 
10 
10 
9* 
20* 
10* 
 
I 
I 
I 
I/II 
I/II 
 
completed 
completed 
unknown 
recruiting 
unknown  
 
 
Gene therapy 
    
  
Adenoviral-mediated 
IFN-β 
 
    
 
BG00001 
 
NCT00299962 
NCT00066404 
 
 
18* 
- 
 
I 
I 
 
ongoing 
unknown 
 
Adoptive T Cell 
Immunotherapy  
    
 
Autologous T cells 
 
NCT01355965 
 
 
18 
 
I 
 
ongoing 
 
Adoptive Transfer of re-
directed T cells 
 
 
NCT01722149 
 
 
6* 
 
I 
 
recruiting 
 
Tyrosine kinase 
inhibitors  
 
    
 
EGF inhibitors 
    
Gefinitib (ZD1839, 
Iressa) 
NCT00025207 40 II 
 
completed 
 
Erlotinib ( OSI-
774,Tarceva) 
 
NCT00039182 
NCT00137826 
 
55 
37 
 
II  
II 
 
 
completed 
completed 
Cetuximab (Ertibux)  NCT00996567 22 II 
 
completed 
 
Anti-angiogensis 
inhbitors  
 
    
Vatalanib 
 
NCT00053885 47 II completed 
 
Sorafenib 
 
NCT00794859 
 
54* 
 
II 
 
unknown 
 
Sunitinib 
 
 
NCT00392444 
 
39 
 
II  
 
completed 
 
Imatinib (Glicev) 
 
 
NCT00402766 
NCT02303899 
 
19 
22 
 
I 
II 
 
completed 
ongoing 
  
Cediranib (AZD2171) 
 
 
NCT00243074 
NCT00243074 
NCT01064648 
 
 
54 
54 
116* 
 
II  
II 
I/II 
 
completed 
completed  
ongoing 
 
Nintedanib  
 
NCT02568449 
NCT02863055 
NCT01907100 
 
 
55 * 
116* 
537* 
 
II 
II 
III 
 
recruiting not yet 
recruiting 
recruiting 
 
Bevacizumab 
 
 
NCT00295503 
NCT00651456 
 
 
53 
448 
 
II 
III 
 
completed 
completed 
 
Histone deacetylase 
inhibitors 
    
 
 
Vorinostat (MK-0683)  
 
 
 
NCT00128102 
 
 
662 
 
 
III  
 
 
completed 
 
Belinostat 
 
 
NCT00365053 
 
13 
 
II 
 
completed 
 
FAK inhibitors 
    
     
Defactinib (VS-6063) 
 
GSK2256098  
 
NCT01870609 
 
NCT01938443 
344 
 
34 
II 
 
I 
terminated 
 
completed 
 
 
NF-κB pathway 
inhibitor 
 
Bortezomib 
 
 
 
 
 
NCT00513877 
 
 
 
 
33 
 
 
 
 
II 
 
 
 
 
completed 
 
IGF-IR inhibitor  
    
 
Cixutumumab 
 
NCT01160458 
 
 
20 
 
II 
 
ongoing 
 
Cytotoxic RNase 
    
 
Ranpirnase 
(ONCONASE) 
 
NCT00003034 
 
300 
 
III 
 
unknown 
     
 A recombinant protein 
hTNF-α fused with a 
peptide 
    
 
NGR-hTNF 
 
NCT01358084 
NCT01098266 
 
 
 
100* 
390* 
 
II 
III 
 
recruiting 
ongoing 
 
Anti-TGF Monoclonal 
Antibody 
    
 
 GC1008 
 
 
NCT01112293 
 
 
14 
 
II 
 
completed 
 
HSP90 inhibitor 
    
 
Ganetespib 
 
NCT01590160 
 
 
27 
 
 
I/II 
 
ongoing 
 
EZH2 inhibitor 
    
 
Tazemetostat 
 
 
NCT02860286 
NCT02875548 
 
 
67* 
300* 
 
 
II 
II 
 
recruiting 
recruiting 
 
MET receptor tyrosine 
kinase inhibitor 
 
    
Tivantinib NCT01861301 
NCT02049060 
 
18 
31 
II 
I/II 
terminated 
ongoing 
 
CSC inhibitor 
    
 
 
 
BBI608  
 
 
NCT02347917 
 
24 
 
I/II 
 
ongoing 
 
Mimic microRNA 
treatment 
 
    
 
TargomiRs 
 
 
NCT02369198 
 
27 
 
I 
 
completed 
 
* Estimated number of participants 
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Table 1 Legend: 
A detailed overview of numerous clinical trials across numerous therapeutic approaches in 
mesothelioma. Targets under investigation and the specific drug or inhibitor used are detailed, 
as is a hyperlink of the ClinicalTrials.gov identifier, in addition to the number of patients 
enrolled, the phase of the trial, and its current status. 
 
Figure 1 Legend: 
Overview of different therapeutic strategies. Closed arrows represent inhibition whilst directed 
arrows represent activation or stimulation. 
  
 Figure 1: Overview of different therapeutic strategies. Closed arrows represent inhibition 
whilst directed arrows represent activation or stimulation. 
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